167 related articles for article (PubMed ID: 15151477)
1. Rationale for aggressive lipid lowering: evidence from clinical trials.
Farmer JA
Expert Rev Cardiovasc Ther; 2004 May; 2(3):305-9. PubMed ID: 15151477
[No Abstract] [Full Text] [Related]
2. The case for medical treatment in chronic stable coronary artery disease.
Nash DT
Arch Intern Med; 2005 Dec 12-26; 165(22):2587-9, discussion 2593-4. PubMed ID: 16344414
[No Abstract] [Full Text] [Related]
3. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease.
van der Harst P; Wagenaar LJ; Buikema H; Voors AA; Plokker HW; Morshuis WJ; Six AJ; Boonstra PW; Nickenig G; Wassmann S; van Veldhuisen DJ; van Gilst WH
Am J Cardiol; 2005 Nov; 96(10):1361-4. PubMed ID: 16275178
[TBL] [Abstract][Full Text] [Related]
4. Assessment of compliance with lipid guidelines in an academic medical center.
Schwiesow SJ; Nappi JM; Ragucci KR
Ann Pharmacother; 2006 Jan; 40(1):27-31. PubMed ID: 16352778
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering medications: what the new guidelines and data mean to women.
Schwartz JB
J Gend Specif Med; 2001; 4(2):9-13. PubMed ID: 11480105
[No Abstract] [Full Text] [Related]
6. Current drug treatments for lipid management.
Stone NJ
Manag Care; 2002 Sep; 11(9 Suppl):4-9. PubMed ID: 12369341
[No Abstract] [Full Text] [Related]
7. [Prevention in coronary heart disease. Can a CSE inhibitor arrest calcium deposits?].
MMW Fortschr Med; 2001 Apr; 143(14):44. PubMed ID: 11340911
[No Abstract] [Full Text] [Related]
8. Clinical trials and tribulations. Cholesterol veers off script.
Couzin J
Science; 2008 Oct; 322(5899):220-3. PubMed ID: 18845747
[No Abstract] [Full Text] [Related]
9. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
Koren MJ; Hunninghake DB;
J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
[TBL] [Abstract][Full Text] [Related]
10. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
11. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
13. New options in lipid management--can we extend the benefits of current therapy? Introduction.
Gotto AM; Paoletti R
Am Heart J; 2002 Dec; 144(6 Suppl):S19-20. PubMed ID: 12486411
[No Abstract] [Full Text] [Related]
14. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
McKenney JM
Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
[TBL] [Abstract][Full Text] [Related]
15. Update on lipid-lowering therapy and LDL-cholesterol targets.
Wiviott SD; Cannon CP
Nat Clin Pract Cardiovasc Med; 2006 Aug; 3(8):424-36. PubMed ID: 16874355
[TBL] [Abstract][Full Text] [Related]
16. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].
Motz W
MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487
[No Abstract] [Full Text] [Related]
17. Lipid-altering therapies and the progression of atherosclerotic disease.
Wierzbicki AS
Cardiovasc Intervent Radiol; 2007; 30(2):155-60. PubMed ID: 17206389
[TBL] [Abstract][Full Text] [Related]
18. Risk reduction strategies in coronary artery disease.
Gibson TM; Ratts T
J La State Med Soc; 2001 Jun; 153(6):312-9. PubMed ID: 11480382
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of dyslipidemia].
Cybulska B
Pol Merkur Lekarski; 2002 Nov; 13 Suppl 1():11-2. PubMed ID: 12621774
[No Abstract] [Full Text] [Related]
20. Vascular disease, hypertension, and prevention.
Lavie CJ
J Am Coll Cardiol; 2004 Jul; 44(2 Suppl A):19A-22A. PubMed ID: 15261686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
